The cost-effectiveness analysis of maintenance olaparib plus Bevacizumab in patients with advanced ovarian cancer: based on the final survival results from PAOLA-1 trial

INTRODUCTION: In 2023, the final PAOLA-1 trial (NCT02477644) survival data were published documenting the benefits of therapy consisting of olaparib plus bevacizumab for patients with advanced ovarian cancer (AOC) as a function of molecular status. In light of these new data, the present study was c...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Youwen, Liu, Kun, Cao, Hui, Zhu, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441725/
https://www.ncbi.nlm.nih.gov/pubmed/37605274
http://dx.doi.org/10.1186/s13048-023-01257-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441725/
https://www.ncbi.nlm.nih.gov/pubmed/37605274
http://dx.doi.org/10.1186/s13048-023-01257-4

Ejemplares similares